A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.
Master's course give graduates a degree of entrepreneurship
5 March 2013
"With coffee mornings, where students meet technology bosses, and a series of networking events, we are playing a lead role in the government's Silicon Roundabout technology enterprise zone," says Dr Dave Chapman (UCL Enterprise). Read: Guardian